Shortlysts - In one of the most significant changes to pharmaceutical pricing in years, President Trump announced a landmark agreement with Pfizer to reduce prescription drug costs in the U.S. The deal, unveiled in conjunction with Pfizer executives, includes substantial reductions in medication prices and a commitment to major investment in domestic research and manufacturing.
Under the agreement, Pfizer will lower Medicaid drug prices to match
those in other developed nations. This addresses criticism that
Americans pay more for medicine than patients in other countries. The
company will also apply ‘most-favored-nation’ pricing to all new U.S.
drugs. This ensures that Americans receive the lowest prices.Zz |
In exchange, the Trump administration will give Pfizer tariff relief and a three-year reprieve from new pharmaceutical tariffs. Pfizer also pledged $70 billion for U.S. research and expanded its manufacturing capabilities. The company will launch TrumpRx in 2026, selling discounted drugs directly to consumers. Some treatments may see price cuts of up to 85%. |
No comments:
Post a Comment